Lexicon Pharmaceuticals (LXRX) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026Pipeline and catalysts
Strategic focus on serious cardiometabolic disease, with late- and early-stage programs advancing across the pipeline.
Sotagliflozin’s phase III SONATA trial in HCM is fully enrolled, with a Q1 2027 readout; type 1 diabetes NDA resubmission is planned for Q1 2027, with potential approval in 2027.
AAK1 diabetic peripheral neuropathy program is phase III-ready; work continues across additional AAK1 indications, while Novo Nordisk-partnered LX9851 is in obesity and other indications.
SONATA and HCM opportunity
SONATA enrolled 542 patients: 440 non-obstructive and 102 obstructive; about 40 patients were taking a cardiac myosin inhibitor at entry.
Primary endpoint is KCCQ change at week 24 across obstructive and non-obstructive HCM; the study was powered for an approximately five-point placebo-adjusted difference.
Management expects a similar KCCQ effect across both subgroups, citing sotagliflozin’s proposed diastolic effects; it highlighted substantial unmet need in non-obstructive HCM.
Rationale includes dual SGLT1/2 activity, myocardial SGLT1 expression, effects on thromboembolic mechanisms, and cardiorenal benefits; management characterized the medicine as once-daily, oral, safe and tolerable.
Q1 topline is expected to include the primary endpoint across the combined population and safety details; most secondary endpoints are planned for a later medical meeting.
Type 1 diabetes and safety
FDA discussions aligned on at least 200 patient-years of exposure and a DKA rate below the inTandem program’s ~3.5 cases per 100 patient-years.
STENO1 data through end-August met both criteria, with 200 patient-years of exposure and ~1 DKA case per 100 patient-years, similar to untreated controls and below inTandem; enrollment continues.
Management said the additional safety criteria were met and the resubmission file is being prepared; sotagliflozin could be the first and only adjunct to insulin for type 1 diabetes.
Latest events from Lexicon Pharmaceuticals
- SONATA-HCM results and a ZYNQUISTA resubmission are targeted for Q1 2027.LXRX
Q3 2026 - Late-stage pipeline advances and key trial readouts set up major milestones by early 2027.LXRX
H.C. Wainwright 28th Annual Global Investment Conference - Phase III HCM data for sotagliflozin expected Q1, with strong pipeline and regulatory momentum.LXRX
12th Annual Cantor Fitzgerald Global Healthcare Conference - SONATA-HCM phase III data expected Q1 2027, with T1D resubmission and pipeline advances underway.LXRX
Citigroup’s Biopharma Back to School Summit 2026 - Shares registered for resale by warrant holders; no proceeds to company; focus on heart failure drugs.LXRX
Registration filing - Q2 2026 net loss was $31.8M; SONATA-HCM Phase 3 enrollment completed, NDA resubmission Q4 2026.LXRX
Q2 2026 - Major clinical and partnership milestones achieved, with pivotal data and regulatory catalysts ahead.LXRX
Evercore ISI 8th Annual HealthCONx Conference - Multiple late-stage programs approach pivotal milestones, with regulatory and clinical catalysts ahead.LXRX
Jefferies London Healthcare Conference 2024 - LX9211 and pilavapadin advance as non-opioid therapies with imminent phase IIb data in DPNP.LXRX
R&D Day 2025